ZEB1 and colorectal carcinoma: By blocking the glycosylase N-methyl-purine glycosylase (MPG), which promotes colitis and inflammation-related CRC in epithelial cells, ZEB1 also offers new therapeutic approaches for controlling inflammation and inflammation-related malignancies [70].